"Yaron brings a rich customer point of view to Treato, the result of his many years at prominent healthcare advertising agencies and his close work with pharmaceutical brand management executives."
New York, NY (PRWEB) November 14, 2012
Treato, the social health intelligence provider, today announced the appointment of Yaron Landow as vice president of US sales and business development. He will be based in the company's newly established New York office, extending the reach of the Israeli-headquartered company.
"Yaron brings a rich customer point of view to Treato, the result of his many years at prominent healthcare advertising agencies and his close work with pharmaceutical brand management executives," said Ido Hadari, president of Treato. "We are already enjoying his valuable contribution to the Treato team and expect him to further drive business growth for the company."
Mr. Landow has over a decade of healthcare ad agency experience in which he established and broadened the reach of leading pharmaceutical brands. He held a series of leadership roles in Omnicom and Publicis agencies, two of the largest healthcare communication, advertising and marketing groups. In his most recent role at Flashpoint Medica (part of the Omnicom network), he led the agency's strategic services and business development departments, overseeing notable new business wins and key account growth.
"I am excited to join Treato since I was impressed by Treato’s innovative offering," Mr. Landow said. "This unique technology brings clear business value to agencies and pharma marketers throughout the brand management lifecycle, enabling new insights from patients, advanced analytics and real-time engagement. I look forward to working with our customers and partners in bringing to market the next level in patient intelligence."
Treato is a new platform of patient intelligence based on online discussions about real life experiences. To date, over a billion patient discussions from forums and blogs have been analyzed, generating the collective patient voice for the very first time. The company is privately held and backed by Reed Elsevier Ventures and a group of private investors.